Gamal E Shiha
Overview
Explore the profile of Gamal E Shiha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shaker M, Ghani A, Shiha G, Ibrahim T, Mehal W
Biochim Biophys Acta
. 2013 Mar;
1833(8):1992-2003.
PMID: 23499874
Increasing hepatic stellate cell (HSC) death is a very attractive approach for limiting liver fibrosis. Tyrosine kinase inhibitors have been shown to have anti-fibrotic properties, but the mechanisms are poorly...
12.
Attallah A, Abdallah S, Attallah A, Omran M, Farid K, Nasif W, et al.
Ann Hepatol
. 2013 Jan;
12(1):44-53.
PMID: 23293193
Background: Several noninvasive predictive models were developed to substitute liver biopsy for fibrosis assessment. Aim: To evaluate the diagnostic value of fibronectin which reflect extracellular matrix metabolism and standard liver...
13.
El-Mezayen H, Toson E, Shiha G
Eur J Gastroenterol Hepatol
. 2012 Sep;
25(1):69-76.
PMID: 23011038
Background/aims: Liver biopsy is considered a gold standard for fibrosis staging, but it has a high risk of morbidity. Therefore, there is an interest in developing noninvasive markers for the...
14.
Shaker M, Shiha G, Ibrahim T
Eur J Pharmacol
. 2011 Sep;
670(2-3):593-600.
PMID: 21925495
Our previous study has already confirmed a promising anti-fibrotic activity especially for nilotinib; when given at a daily dose of 10 mg/kg during the last 4 weeks of thioacetamide (TAA)-induced...
15.
Shaker M, Zalata K, Mehal W, Shiha G, Ibrahim T
Toxicol Appl Pharmacol
. 2011 Feb;
252(2):165-75.
PMID: 21316382
Effective and well-tolerated anti-fibrotic drugs are currently lacking. Therefore, this study was carried out to investigate the potential anti-fibrotic effects of imatinib, nilotinib and silymarin on established hepatic fibrosis in...
16.
Shaker M, Salem H, Shiha G, Ibrahim T
Fundam Clin Pharmacol
. 2010 Apr;
25(2):248-57.
PMID: 20408881
The aim of this study was to evaluate and compare the effects of imatinib and nilotinib to that of silymarin on established liver fibrosis and oxidative stress in a thioacetamide...
17.
Attallah A, Shiha G, Ismail H, Mansy S, El-Sherbiny R, El-Dosoky I
Clin Biochem
. 2008 Dec;
42(6):455-61.
PMID: 19063876
Objectives: Hepatitis C virus (HCV) is a major aetiological agent of chronic hepatitis and it leads to the development of liver cirrhosis and hepatocellular carcinoma (HCC). The significances of p53...
18.
Attallah A, Ismail H, Shiha G, Abou-Dobara M, El-Sherbiny R, El-Dosoky I
Clin Chim Acta
. 2007 Nov;
388(1-2):115-22.
PMID: 18021744
Background: The identification of native HCV antigens may prove very useful in the diagnosis and early treatment of HCV infection. Here, we aimed to identify and partially characterize a native...
19.
Attallah A, Zahran F, Ismail H, Omran M, El-Dosoky I, Shiha G
J Immunoassay Immunochem
. 2007 Sep;
28(4):331-42.
PMID: 17885887
Serum tests measuring the dynamic processes of fibrogenesis and fibrolysis may reflect the severity of liver disease. Fibronectin plays a role in liver fibrosis. The aim of this study was...
20.
Attallah A, Toson E, El-Waseef A, Abo-Seif M, Omran M, Shiha G
Clin Chim Acta
. 2006 Mar;
369(1):66-72.
PMID: 16545356
Background/aims: The invasive liver biopsy is still considered the gold standard for assessing patients with chronic hepatitis C (CHC). Our aim was to determine the operating characteristics of a non-invasive...